Tocqueville Asset Management L.P. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,378 shares of the biopharmaceutical company’s stock after selling 282 shares during the period. Tocqueville Asset Management L.P.’s holdings in Regeneron Pharmaceuticals were worth $4,640,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the business. Alpha Windward LLC boosted its holdings in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares during the period. Regentatlantic Capital LLC lifted its stake in Regeneron Pharmaceuticals by 0.9% in the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5 shares in the last quarter. Capital Planning Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 2.1% in the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 12 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 1.7% in the second quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 12 shares in the last quarter. Finally, Princeton Capital Management Inc. lifted its stake in Regeneron Pharmaceuticals by 0.6% in the second quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 15 shares in the last quarter. 67.80% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have weighed in on REGN. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $425.00 price target (down previously from $473.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 9th. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Citigroup Inc. reiterated a “buy” rating and issued a $480.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price objective on the stock in a report on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $481.49.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down $8.82 on Wednesday, hitting $384.80. The company had a trading volume of 1,109,100 shares, compared to its average volume of 903,660. Regeneron Pharmaceuticals, Inc. has a 12 month low of $340.09 and a 12 month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The company has a market cap of $42,176.78, a PE ratio of 34.08, a P/E/G ratio of 1.55 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same period last year, the business earned $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman P Roy Vagelos sold 1,305 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $470.00, for a total value of $613,350.00. Following the transaction, the chairman now owns 329,543 shares in the company, valued at $154,885,210. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 77,956 shares of company stock worth $36,898,788. Company insiders own 10.80% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.